| Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients E Morsia, K McCullough, M Joshi, J Cook, HB Alkhateeb, A Al‐Kali, ... American journal of hematology 95 (12), 1511-1521, 2020 | 107 | 2020 |
| Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases N Gangat, P Guglielmelli, N Szuber, KH Begna, MM Patnaik, MR Litzow, ... American journal of hematology 96 (7), 781-789, 2021 | 58 | 2021 |
| Vancomycin‐resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic … M Hefazi, M Damlaj, HB Alkhateeb, DK Partain, R Patel, RR Razonable, ... Transplant Infectious Disease 18 (6), 913-920, 2016 | 52 | 2016 |
| Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease FF Yalniz, M Hefazi, K McCullough, MR Litzow, WJ Hogan, R Wolf, ... Biology of Blood and Marrow Transplantation 23 (9), 1478-1484, 2017 | 47 | 2017 |
| Cessation of medication for people with schizophrenia already stable on chlorpromazine MQ Almerie, H Alkhateeb, A Essali, HE Matar, E Rezk, ... Cochrane Database of Systematic Reviews 2013 (12), 1996 | 43 | 1996 |
| Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms HB Alkhateeb, A Nanaa, D Viswanatha, JM Foran, T Badar, L Sproat, ... Blood advances 6 (2), 528-532, 2022 | 38 | 2022 |
| Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients M Li, M Binder, T Lasho, A Ferrer, N Gangat, A Al-Kali, A Mangaonkar, ... Blood Advances 5 (8), 2272-2278, 2021 | 34 | 2021 |
| Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients AA Mangaonkar, KJ Langer, TL Lasho, C Finke, MR Litzow, WJ Hogan, ... John Wiley & Sons, Inc., 2023 | 33 | 2023 |
| Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation M Joshi, J Cook, K McCullough, A Nanaa, N Gangat, JM Foran, ... Blood cancer journal 11 (3), 49, 2021 | 33 | 2021 |
| Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing M Damlaj, HB Alkhateeb, M Hefazi, DK Partain, S Hashmi, DA Gastineau, ... Biology of Blood and Marrow Transplantation 22 (8), 1431-1439, 2016 | 33 | 2016 |
| Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia P Pophali, A Matin, AA Mangaonkar, R Carr, M Binder, A Al-Kali, ... Blood cancer journal 10 (11), 121, 2020 | 31 | 2020 |
| Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma HB Alkhateeb, R Mohty, P Greipp, R Bansal, M Hathcock, A Rosenthal, ... Blood cancer journal 12 (7), 113, 2022 | 29 | 2022 |
| Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia N Gangat, I Johnson, K McCullough, F Farrukh, A Al-Kali, H Alkhateeb, ... Haematologica 107 (10), 2501, 2022 | 27 | 2022 |
| Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients N Gangat, O Karrar, M Iftikhar, K McCullough, IM Johnson, M Abdelmagid, ... American journal of hematology 99 (2), 193-202, 2024 | 26 | 2024 |
| JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy N Gangat, N Szuber, H Alkhateeb, A Al-Kali, A Pardanani, A Tefferi Blood, The Journal of the American Society of Hematology 138 (26), 2886-2889, 2021 | 26 | 2021 |
| Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute … R He, DJ Devine, ZJ Tu, M Mai, D Chen, PL Nguyen, JL Oliveira, ... Modern Pathology 33 (3), 334-343, 2020 | 26 | 2020 |
| Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia AA Mangaonkar, KK Reichard, M Binder, G Coltro, TL Lasho, RM Carr, ... Blood Advances 4 (21), 5425-5430, 2020 | 24 | 2020 |
| Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts AA Mangaonkar, TL Lasho, CM Finke, N Gangat, A Al-Kali, MA Elliott, ... Blood cancer journal 8 (2), 18, 2018 | 24 | 2018 |
| Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant … Y Inamoto, I Petriček, L Burns, S Chhabra, Z DeFilipp, P Hematti, A Rovó, ... Bone marrow transplantation 54 (5), 648-661, 2019 | 23 | 2019 |
| Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer KV Giridhar, C Sanhueza, DW Hillman, H Alkhateeb, R Carlson, W Tan, ... Prostate cancer and prostatic diseases 21 (3), 431-437, 2018 | 23 | 2018 |
